Prognostic Model for Metastatic Melanoma
Author Information
Author(s): Schmidt H, Bastholt L, Geertsen P, Christensen I J, Larsen S, Gehl J, von der Maase H
Primary Institution: Aarhus University Hospital
Hypothesis
Elevated neutrophil and monocyte counts in peripheral blood are associated with poor survival in patients with metastatic melanoma.
Conclusion
Elevated neutrophil and monocyte counts, along with elevated LDH and poor performance status, are independent prognostic factors for poor survival in metastatic melanoma patients.
Supporting Evidence
- Elevated LDH was identified as a significant prognostic factor for poor survival.
- Patients with elevated neutrophil counts had a higher risk of poor outcomes.
- The proposed prognostic model was validated through cross-validation techniques.
Takeaway
Doctors found that high levels of certain blood cells can help predict how long patients with advanced skin cancer might live.
Methodology
The study analyzed data from 321 patients receiving IL-2-based immunotherapy, assessing various prognostic factors through univariate and multivariate Cox's regression analyses.
Limitations
The study's findings may not directly apply to patients treated with high-dose intravenous IL-2.
Participant Demographics
Patients were adults with biopsy-verified stage IV metastatic melanoma.
Statistical Information
P-Value
p<0.001
Confidence Interval
95% CI, 11.4–13.8 for low-risk group; 95% CI, 4.8–7.2 for intermediate-risk group; 95% CI, 1.2–5.6 for high-risk group.
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website